Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni: Felnott- vagy gyermekintézményben?

Translated title of the contribution: Hodgkin's lymphoma in adolescents

J. Müller, Zsuzsanna Molnár, A. Illés, Monika Csóka, Zsuzsanna Jakab, Beáta Deák, Tamás Schneider, Erika Várady, András Rosta, Zsófia Simon, Katalin Keresztes, L. Gergely, Gábor Kovács

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards. Aim: The aim of our work was to compare the treatment modalities and the survival rates in adolescents with HL treated in adult (A) or pediatric (P) institutes. Methods: From January 1990 to December 2004, 138 patients (14-21 years) with HL were treated in two adult institutes (A) and 107 in the 10 centres of the Hungarian Pediatric Oncology Network (P). Results: Male:female ratio was 1:1.15 (A) and 1:1.38 (P). The mean age was 18.6 (A) and 15.7 (P) years. There was no difference between the distribution of the stages in the two patient groups. The distribution of histological subtypes (A and P): nodular sclerosing 47% and 59%, mixed ceflularity 45% and 25%, lymphocyte rich 1.5% and 10%, lymphocyte depleted 4% and 1%, nodular lymphocyte predominant 1.5% and 3% and unknown 1% and 2%. The majority of the patients were treated with ABVD (A) and OPPA/OEPA±COPP (P). One hundred and fifteen (A) and 97 (P) adolescents received irradiation therapy. 80% (A) and 91% (A) of the patients got radiotherapy. In group A 14%, in group P 13% of the patients had relapse. In group A 16 patients died and in group P 7. There was no significant difference in the overall survival (OS) rates at 5 and 10 years in the two patient groups. The event-free survival (EFS) was 76.5±4% and 72.5±4% at 5 and 10 years in group A, and 85.3±4% at both times in group P (p = 0.0452). Conclusion: Survival rates in HL are quite high, 80-90% of the patients can be cured. Event-free survival was higher in pediatric than in adult institutes. In case of patients younger than 18 years, the survival rates were much better in pediatric institutes, so these patients should be treated in pediatric institutes or with protocols used by the pediatricians.

Original languageHungarian
Pages (from-to)2221-2227
Number of pages7
JournalOrvosi Hetilap
Volume149
Issue number47
DOIs
Publication statusPublished - Nov 23 2008

Fingerprint

Hodgkin Disease
Pediatrics
Survival Rate
Lymphocytes
Disease-Free Survival
Radiotherapy
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni : Felnott- vagy gyermekintézményben? / Müller, J.; Molnár, Zsuzsanna; Illés, A.; Csóka, Monika; Jakab, Zsuzsanna; Deák, Beáta; Schneider, Tamás; Várady, Erika; Rosta, András; Simon, Zsófia; Keresztes, Katalin; Gergely, L.; Kovács, Gábor.

In: Orvosi Hetilap, Vol. 149, No. 47, 23.11.2008, p. 2221-2227.

Research output: Contribution to journalArticle

Müller, J, Molnár, Z, Illés, A, Csóka, M, Jakab, Z, Deák, B, Schneider, T, Várady, E, Rosta, A, Simon, Z, Keresztes, K, Gergely, L & Kovács, G 2008, 'Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni: Felnott- vagy gyermekintézményben?', Orvosi Hetilap, vol. 149, no. 47, pp. 2221-2227. https://doi.org/10.1556/OH.2008.28447
Müller, J. ; Molnár, Zsuzsanna ; Illés, A. ; Csóka, Monika ; Jakab, Zsuzsanna ; Deák, Beáta ; Schneider, Tamás ; Várady, Erika ; Rosta, András ; Simon, Zsófia ; Keresztes, Katalin ; Gergely, L. ; Kovács, Gábor. / Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni : Felnott- vagy gyermekintézményben?. In: Orvosi Hetilap. 2008 ; Vol. 149, No. 47. pp. 2221-2227.
@article{f3a8d97772e94a23a1eb4a7ae49f8057,
title = "Hodgkin-lymphoma adolescens korban. Hol {\'e}rdemes kezelni: Felnott- vagy gyermekint{\'e}zm{\'e}nyben?",
abstract = "Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards. Aim: The aim of our work was to compare the treatment modalities and the survival rates in adolescents with HL treated in adult (A) or pediatric (P) institutes. Methods: From January 1990 to December 2004, 138 patients (14-21 years) with HL were treated in two adult institutes (A) and 107 in the 10 centres of the Hungarian Pediatric Oncology Network (P). Results: Male:female ratio was 1:1.15 (A) and 1:1.38 (P). The mean age was 18.6 (A) and 15.7 (P) years. There was no difference between the distribution of the stages in the two patient groups. The distribution of histological subtypes (A and P): nodular sclerosing 47{\%} and 59{\%}, mixed ceflularity 45{\%} and 25{\%}, lymphocyte rich 1.5{\%} and 10{\%}, lymphocyte depleted 4{\%} and 1{\%}, nodular lymphocyte predominant 1.5{\%} and 3{\%} and unknown 1{\%} and 2{\%}. The majority of the patients were treated with ABVD (A) and OPPA/OEPA±COPP (P). One hundred and fifteen (A) and 97 (P) adolescents received irradiation therapy. 80{\%} (A) and 91{\%} (A) of the patients got radiotherapy. In group A 14{\%}, in group P 13{\%} of the patients had relapse. In group A 16 patients died and in group P 7. There was no significant difference in the overall survival (OS) rates at 5 and 10 years in the two patient groups. The event-free survival (EFS) was 76.5±4{\%} and 72.5±4{\%} at 5 and 10 years in group A, and 85.3±4{\%} at both times in group P (p = 0.0452). Conclusion: Survival rates in HL are quite high, 80-90{\%} of the patients can be cured. Event-free survival was higher in pediatric than in adult institutes. In case of patients younger than 18 years, the survival rates were much better in pediatric institutes, so these patients should be treated in pediatric institutes or with protocols used by the pediatricians.",
keywords = "Adolescent, Chemotherapy, Hodgkin lymphoma, Survival",
author = "J. M{\"u}ller and Zsuzsanna Moln{\'a}r and A. Ill{\'e}s and Monika Cs{\'o}ka and Zsuzsanna Jakab and Be{\'a}ta De{\'a}k and Tam{\'a}s Schneider and Erika V{\'a}rady and Andr{\'a}s Rosta and Zs{\'o}fia Simon and Katalin Keresztes and L. Gergely and G{\'a}bor Kov{\'a}cs",
year = "2008",
month = "11",
day = "23",
doi = "10.1556/OH.2008.28447",
language = "Hungarian",
volume = "149",
pages = "2221--2227",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "47",

}

TY - JOUR

T1 - Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni

T2 - Felnott- vagy gyermekintézményben?

AU - Müller, J.

AU - Molnár, Zsuzsanna

AU - Illés, A.

AU - Csóka, Monika

AU - Jakab, Zsuzsanna

AU - Deák, Beáta

AU - Schneider, Tamás

AU - Várady, Erika

AU - Rosta, András

AU - Simon, Zsófia

AU - Keresztes, Katalin

AU - Gergely, L.

AU - Kovács, Gábor

PY - 2008/11/23

Y1 - 2008/11/23

N2 - Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards. Aim: The aim of our work was to compare the treatment modalities and the survival rates in adolescents with HL treated in adult (A) or pediatric (P) institutes. Methods: From January 1990 to December 2004, 138 patients (14-21 years) with HL were treated in two adult institutes (A) and 107 in the 10 centres of the Hungarian Pediatric Oncology Network (P). Results: Male:female ratio was 1:1.15 (A) and 1:1.38 (P). The mean age was 18.6 (A) and 15.7 (P) years. There was no difference between the distribution of the stages in the two patient groups. The distribution of histological subtypes (A and P): nodular sclerosing 47% and 59%, mixed ceflularity 45% and 25%, lymphocyte rich 1.5% and 10%, lymphocyte depleted 4% and 1%, nodular lymphocyte predominant 1.5% and 3% and unknown 1% and 2%. The majority of the patients were treated with ABVD (A) and OPPA/OEPA±COPP (P). One hundred and fifteen (A) and 97 (P) adolescents received irradiation therapy. 80% (A) and 91% (A) of the patients got radiotherapy. In group A 14%, in group P 13% of the patients had relapse. In group A 16 patients died and in group P 7. There was no significant difference in the overall survival (OS) rates at 5 and 10 years in the two patient groups. The event-free survival (EFS) was 76.5±4% and 72.5±4% at 5 and 10 years in group A, and 85.3±4% at both times in group P (p = 0.0452). Conclusion: Survival rates in HL are quite high, 80-90% of the patients can be cured. Event-free survival was higher in pediatric than in adult institutes. In case of patients younger than 18 years, the survival rates were much better in pediatric institutes, so these patients should be treated in pediatric institutes or with protocols used by the pediatricians.

AB - Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards. Aim: The aim of our work was to compare the treatment modalities and the survival rates in adolescents with HL treated in adult (A) or pediatric (P) institutes. Methods: From January 1990 to December 2004, 138 patients (14-21 years) with HL were treated in two adult institutes (A) and 107 in the 10 centres of the Hungarian Pediatric Oncology Network (P). Results: Male:female ratio was 1:1.15 (A) and 1:1.38 (P). The mean age was 18.6 (A) and 15.7 (P) years. There was no difference between the distribution of the stages in the two patient groups. The distribution of histological subtypes (A and P): nodular sclerosing 47% and 59%, mixed ceflularity 45% and 25%, lymphocyte rich 1.5% and 10%, lymphocyte depleted 4% and 1%, nodular lymphocyte predominant 1.5% and 3% and unknown 1% and 2%. The majority of the patients were treated with ABVD (A) and OPPA/OEPA±COPP (P). One hundred and fifteen (A) and 97 (P) adolescents received irradiation therapy. 80% (A) and 91% (A) of the patients got radiotherapy. In group A 14%, in group P 13% of the patients had relapse. In group A 16 patients died and in group P 7. There was no significant difference in the overall survival (OS) rates at 5 and 10 years in the two patient groups. The event-free survival (EFS) was 76.5±4% and 72.5±4% at 5 and 10 years in group A, and 85.3±4% at both times in group P (p = 0.0452). Conclusion: Survival rates in HL are quite high, 80-90% of the patients can be cured. Event-free survival was higher in pediatric than in adult institutes. In case of patients younger than 18 years, the survival rates were much better in pediatric institutes, so these patients should be treated in pediatric institutes or with protocols used by the pediatricians.

KW - Adolescent

KW - Chemotherapy

KW - Hodgkin lymphoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=57049150778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049150778&partnerID=8YFLogxK

U2 - 10.1556/OH.2008.28447

DO - 10.1556/OH.2008.28447

M3 - Article

C2 - 19004744

AN - SCOPUS:57049150778

VL - 149

SP - 2221

EP - 2227

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 47

ER -